SWiss Evaluation of Bioabsorbable Polymer-coated Everolimus-eluting Coronary sTent
- Conditions
- Coronary Artery Disease
- Registration Number
- NCT02150876
- Lead Sponsor
- University of Freiburg
- Brief Summary
Bioresorbable polymer drug eluting stents (DES) are an indisputable improvement over first-generation DES with promising results on long-term adverse events. But the thicker polymer and/or strut may hinder its deliverability. Complex procedures challenge stent deliverability and stent delivery failure impacts clinical prognosis.
This registry aimed to assess the immediate performance of the third-generation Synergy everolimus-eluting stent (sEES) and its 12-month clinical follow-up in an all-comer population.
- Detailed Description
All consecutive patients treated with the SYNERGY stent at our institutions were prospectively included in the SWEET registry. Baseline and procedural characteristics were collected at index procedure. Clinical follow-up was performed at 1 month and 1 year by clinic visit or follow-up call. The study end point was a composite of cardiac death (CD), myocardial infarction (MI) and target lesion revascularization (TLR) at 1 year.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1000
1.Patient treated by everolimus-eluting SYNERGY® stent
- Patient or legal guardian won't give consent to use collected data
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method MACE at 12 month follow up 12-month device-oriented MACE (dMACE) as defined by ARC (cardiac death, MI and TLR).
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
University of Freiburg
🇨🇭Freiburg, Switzerland
University of Freiburg🇨🇭Freiburg, Switzerland